样式: 排序: IF: - GO 导出 标记为已读
-
STING-mediated IL-6 Inhibits OATP1B1 Expression via the TCF4 Signaling Pathway in Cholestasis. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-07-15 Yan Guo,Hongjia Zhang,Nan Zhao,Ying Peng,Dongya Shen,Yubin Chen,Xiaoxun Zhang,Can-E Tang,Jin Chai
Background and Aims Organic anion-transporting polypeptides (OATPs) play a crucial role in the transport of bile acids and bilirubin. In our previous study, interleukin 6 (IL-6) reduced OATP1B3 levels in cholestatic disease. However, it remains unclear whether IL-6 inhibits OATP1B1 expression in cholestatic diseases. This study aimed to investigate whether IL-6 can inhibit OATP1B1 expression and explore
-
Efficacy of Addiction Pharmacotherapy in Alcohol Use Disorder and Their Effects on Liver Health. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-07-01 Jiahua Zhou,Jiajing Li,Qiuwei Pan,Ibrahim Ayada
Both alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease are leading contributors to chronic liver diseases. These conditions often coexist, exacerbating disease progression. Despite ALD being a leading cause of liver transplantation, many individuals with alcohol use disorder (AUD) do not receive treatment. In this review, we discussed the epidemiology
-
Gut Microbiota and Cytokine Profile in Cirrhosis. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-06-28 Irina Efremova,Roman Maslennikov,Anna Kudryavtseva,Anastasia Avdeeva,George Krasnov,Mikhail Diatroptov,Vyacheslav Bakhitov,Salekh Aliev,Natalia Sedova,Maria Fedorova,Elena Poluektova,Oxana Zolnikova,Nariman Aliev,Anna Levshina,Vladimir Ivashkin
Background and Aims Gut dysbiosis and abnormal cytokine profiles are common in cirrhosis. This study aimed to evaluate the correlations between them. Methods In the blood plasma of cirrhosis patients and controls, 27 cytokines were examined using a multiplex assay. The plasma levels of nitrites (stable metabolites of the endothelial dysfunction biomarker nitric oxide) and lipopolysaccharide (LPS) were
-
Systematic Evaluation of Guidelines for the Diagnosis and Treatment of Hepatitis E Virus Infection. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-06-28 Ting Gu,Cai-Ying Zheng,Yan-Qin Deng,Xiao-Feng Yang,Wei-Min Bao,Ying-Mei Tang
Background and Aims The hepatitis E virus (HEV) is a zoonotic disease, and infection with HEV in humans primarily causes acute infections and can progress to chronic manifestation in immunocompromised individuals. Over the past decade, guidelines for diagnosing and treating HEV infection have been developed. This study aimed to systematically assess the quality of current guidelines for diagnosing
-
Oncolytic Virus Senecavirus A Inhibits Hepatocellular Carcinoma Proliferation and Growth by Inducing Cell Cycle Arrest and Apoptosis. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-06-20 Tao Gong,Xiao Liu,Qingyuan Li,Donald R Branch,Melika Loriamini,Wenxian Wen,Yaoqiang Shi,Qi Tan,Bin Fan,Zhonghui Zhou,Yujia Li,Chunhui Yang,Shilin Li,Xiaoqiong Duan,Limin Chen
Background and Aims Hepatocellular carcinoma (HCC) is a highly aggressive tumor with limited treatment options and high mortality. Senecavirus A (SVA) has shown potential in selectively targeting tumors while sparing healthy tissues. This study aimed to investigate the effects of SVA on HCC cells in vitro and in vivo and to elucidate its mechanisms of action. Methods The cell counting kit-8 assay and
-
THR-β Agonist for Nonalcoholic Steatohepatitis Treatment: Challenges of a Promising Drug. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-06-20 Feng Xue,Lai Wei
-
Bacterial Infections in Acute-on-chronic Liver Failure: Epidemiology, Diagnosis, Pathogenesis, and Management. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-06-20 Zhaoyu Xu,Xiuding Zhang,Jiyang Chen,Yu Shi,Shangwei Ji
Acute-on-chronic liver failure (ACLF) is a distinct condition characterized by the abrupt exacerbation of pre-existing chronic liver disease, often leading to multi-organ failures and significant short-term mortalities. Bacterial infection is one of the most frequent triggers for ACLF and a common complication following its onset. The impact of bacterial infections on the clinical course and outcome
-
Heritable Chronic Cholestatic Liver Diseases: A Review. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-06-17 Jasmine Tidwell,George Y Wu
Chronic cholestasis due to heritable causes is usually diagnosed in childhood. However, many cases can present and survive into adulthood. The time course varies considerably depending on the underlying etiology. Laboratory data usually reveal elevated conjugated hyperbilirubinemia, alkaline phosphatase, and gamma-glutamyl transpeptidase. Patients may be asymptomatic; however, when present, the typical
-
Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-06-17 Fanpu Ji,Sally Tran,Eiichi Ogawa,Chung-Feng Huang,Takanori Suzuki,Yu Jun Wong,Hidenori Toyoda,Dae Won Jun,Liu Li,Haruki Uojima,Akito Nozaki,Makoto Chuma,Cheng-Hao Tseng,Yao-Chun Hsu,Masatoshi Ishigami,Takashi Honda,Masanori Atsukawa,Hiroaki Haga,Masaru Enomoto,Huy Trinh,Carmen Monica Preda,Phillip Vutien,Charles Landis,Dong Hyun Lee,Tsunamasa Watanabe,Hirokazu Takahashi,Hiroshi Abe,Akira Asai,Yuichiro
Background and Aims As practice patterns and hepatitis C virus (HCV) genotypes (GT) vary geographically, a global real-world study from both East and West covering all GTs can help inform practice policy toward the 2030 HCV elimination goal. This study aimed to assess the effectiveness and tolerability of DAA treatment in routine clinical practice in a multinational cohort for patients infected with
-
Hydrogen Sulfide Promotes Platelet Autophagy via PDGFR-α/PI3K/Akt Signaling in Cirrhotic Thrombocytopenia. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-06-17 Hua-Xiang Yang,Yang-Jie Li,Yang-Lan He,Ke-Ke Jin,Ling-Na Lyu,Hui-Guo Ding
Background and Aims The role of platelet autophagy in cirrhotic thrombocytopenia (CTP) remains unclear. This study aimed to investigate the impact of platelet autophagy in CTP and elucidate the regulatory mechanism of hydrogen sulfide (H2S) on platelet autophagy. Methods Platelets from 56 cirrhotic patients and 56 healthy individuals were isolated for in vitro analyses. Autophagy markers (ATG7, BECN1
-
TIMP-1 Promotes Expression of MCP-1 and Macrophage Migration by Inducing Fli-1 in Experimental Liver Fibrosis. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-06-11 Xiaoli Huang,Xiaofan Wang,Yanhong Wang,Shuangjun Shen,Wei Chen,Tianhui Liu,Ping Wang,Xu Fan,Lin Liu,Jidong Jia,Min Cong
Background and Aims Tissue inhibitor of metalloproteinase-1 (TIMP-1) plays a role in the excessive generation of extracellular matrix in liver fibrosis. This study aimed to explore the pathways through which TIMP-1 controls monocyte chemoattractant protein-1 (MCP-1) expression and promotes hepatic macrophage recruitment. Methods Liver fibrosis was triggered through carbon tetrachloride, and an adeno-associated
-
Alcoholic Liver Disease in China: A Disease Influenced by Complex Social Factors That Should Not Be Neglected. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-05-31 Xiaofeng Feng,Nafei Huang,Yuqin Wu,Fei Gao,Xiaomei Chen,Chenyi Zhang,Bing Zhang,Tao Sun
Alcoholic liver disease (ALD) encompasses liver damage caused by chronic, excessive alcohol consumption. It manifests initially as marked hepatocellular steatosis and can progress to steatohepatitis, liver fibrosis, and cirrhosis. With China's rapid economic growth, coupled with a complex social background and the influence of a deleterious wine culture, the number of patients with ALD in China has
-
Association of Omega-3 Polyunsaturated Fatty Acids with Sarcopenia in Liver Cirrhosis Patients with Hepatocellular Carcinoma. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-05-31 Akitoshi Sano,Jun Inoue,Eiji Kakazu,Masashi Ninomiya,Mio Tsuruoka,Kosuke Sato,Masazumi Onuki,Satoko Sawahashi,Keishi Ouchi,Atsushi Masamune
Background and Aims Sarcopenia is associated with the prognosis of patients with liver cirrhosis and hepatocellular carcinoma (HCC). Given their diverse physiological activities, we hypothesized that plasma fatty acids might influence the progression of sarcopenia. This study aimed to clarify the association between fatty acids and sarcopenia in cirrhotic patients with HCC. Methods In this single-center
-
PLCG2 Mutation in a Patient Presenting with Type 2 Autoimmune Hepatitis. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-05-28 Antoine Gardin,Léa Gaigne,Aude Magérus,Frédéric Rieux-Laucat,Emmanuel Jacquemin
-
Exploring the Pathogenesis of Autoimmune Liver Diseases from the Heterogeneity of Target Cells. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-05-28 Zi-Xuan Qiu,Lin-Xiang Huang,Xiao-Xiao Wang,Zi-Long Wang,Xiao-He Li,Bo Feng
The incidence of autoimmune liver diseases (ALDs) and research on their pathogenesis are increasing annually. However, except for autoimmune hepatitis, which responds well to immunosuppression, primary biliary cholangitis and primary sclerosing cholangitis are insensitive to immunosuppressive therapy. Besides the known effects of the environment, genetics, and immunity on ALDs, the heterogeneity of
-
"Treat-all" Strategy for Patients with Chronic Hepatitis B Virus Infection in China: Are We There Yet? J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-05-28 Mengyang Zhang,Yuanyuan Kong,Xiaoqian Xu,Yameng Sun,Jidong Jia,Hong You
Chronic hepatitis B remains the primary cause of liver-related events in China. The World Health Organization set a goal to eliminate viral hepatitis as a public health threat by 2030. However, achieving this goal appears challenging due to the current low rates of diagnosis and treatment. The "Treat-all" strategy, which proposes treating all patients with detectable hepatitis B virus (HBV) DNA or
-
Association of Mosaic Chromosomal Alterations and Genetic Factors with the Risk of Cirrhosis. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-05-28 Xinyuan Ge,Lu Zhang,Maojie Liu,Xiao Wang,Xin Xu,Yuqian Yan,Chan Tian,Juan Yang,Yang Ding,Chengxiao Yu,Jing Lu,Longfeng Jiang,Qiang Wang,Qun Zhang,Ci Song
Background and Aims Age-related mosaic chromosomal alterations (mCAs) detected from genotyping of blood-derived DNA are structural somatic variants that indicate clonal hematopoiesis. This study aimed to investigate whether mCAs contribute to the risk of cirrhosis and modify the effect of a polygenic risk score (PRS) on cirrhosis risk prediction. Methods mCA call sets of individuals with European ancestry
-
Mitochondrial GRIM19 Loss Induces Liver Fibrosis through NLRP3/IL33 Activation via Reactive Oxygen Species/NF-кB Signaling. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-05-28 Xiaohui Xu,Jinmei Feng,Xin Wang,Xin Zeng,Ying Luo,Xinyu He,Meihua Yang,Tiewei Lv,Zijuan Feng,Liming Bao,Li Zhao,Daochao Huang,Yi Huang
Background and Aims Hepatic fibrosis (HF) is a critical step in the progression of hepatocellular carcinoma (HCC). Gene associated with retinoid-IFN-induced mortality 19 (GRIM19), an essential component of mitochondrial respiratory chain complex I, is frequently attenuated in various human cancers, including HCC. Here, we aimed to investigate the potential relationship and underlying mechanism between
-
A Blood Hepatocellular Carcinoma Signature Recognizes Very Small Tumor Nodules with Metastatic Traits. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-05-20 Kun Chen,Junxiao Wang,Liping Jiang,Fei Zhao,Ruochan Zhang,Zhiyuan Wu,Dongmei Wang,Yuchen Jiao,Hui Xie,Chunfeng Qu
Background and Aims Hepatocellular carcinoma (HCC) cases with small nodules are commonly treated with radiofrequency ablation (RFA), but the recurrence rate remains high. This study aimed to establish a blood signature for identifying HCC with metastatic traits pre-RFA. Methods Data from HCC patients treated between 2010 and 2017 were retrospectively collected. A blood signature for metastatic HCC
-
Etiologies of Splenic Venous Hypertension: A Review. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-05-20 Jasmine Tidwell,Bianca Thakkar,George Y Wu
Splenic venous hypertension or left-sided portal hypertension is a rare condition caused by an obstruction of the splenic vein. Usually, it presents with upper gastrointestinal bleeding in the absence of liver disease. Etiologies can be classified based on the mechanism of development of splenic vein hypertension: compression, stenosis, inflammation, thrombosis, and surgically decreased splenic venous
-
Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going? J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-05-11 Xin Luo,Lun-Gen Lu
Cholestatic liver disease is a group of diseases in which bile acid accumulates in the liver for various reasons, resulting in abnormal liver biochemical indicators and histological damage. Cholestasis can be divided into intrahepatic cholestasis and extrahepatic cholestasis, which will contribute to liver damage and progress to liver fibrosis and cirrhosis. Primary biliary cholangitis (PBC) and primary
-
Mesenchymal Stem Cells Alleviate Acute Liver Failure through Regulating Hepatocyte Apoptosis and Macrophage Polarization. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-04-30 Yachao Tao,Yonghong Wang,Menglan Wang,Hong Tang,Enqiang Chen
Background and Aims Acute liver failure (ALF) is a life-threatening clinical problem with limited treatment options. Administration of human umbilical cord mesenchymal stem cells (hUC-MSCs) may be a promising approach for ALF. This study aimed to explore the role of hUC-MSCs in the treatment of ALF and the underlying mechanisms. Methods A mouse model of ALF was induced by lipopolysaccharide and d-galactosamine
-
Ultrasonography of Hepatocellular Carcinoma: From Diagnosis to Prognosis. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-04-30 Huisen Hu,Yonglei Zhao,Chengbin He,Lujie Qian,Pintong Huang
Hepatocellular carcinoma (HCC) is a prominent contributor to cancer-related mortality worldwide. Early detection and diagnosis of liver cancer can significantly improve its prognosis and patient survival. Ultrasound technology, serving has undergone substantial advances as the primary method of HCC surveillance and has broadened its scope in recent years for effective management of HCC. This article
-
Dopamine Inhibits the Expression of Hepatitis B Virus Surface and e Antigens by Activating the JAK/STAT Pathway and Upregulating Interferon-stimulated Gene 15 Expression. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-04-30 Xiaoquan Liu,Xiuqing Pang,Zhiping Wan,Jinhua Zhao,Zhiliang Gao,Hong Deng
Background and Aims Hepatitis B virus (HBV) infection is a major risk factor for cirrhosis and liver cancer, and its treatment continues to be difficult. We previously demonstrated that a dopamine analog inhibited the packaging of pregenomic RNA into capsids. The present study aimed to determine the effect of dopamine on the expressions of hepatitis B virus surface and e antigens (HBsAg and HBeAg,
-
Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-04-24 Le Li,Zhen-Zhen Li,Li-Xin Pan,Jia-Yong Su,Shan Huang,Liang Ma,Jian-Hong Zhong
Most patients with hepatocellular carcinoma (HCC) have a poor prognosis. Hepatectomy and local ablation are the main curative treatments for HCC. Nevertheless, the recurrence rate after hepatectomy or ablation is up to 70%, which seriously affects patient prognosis. Several adjuvant therapies have been explored to reduce postoperative recurrence. However, although a variety of adjuvant therapies have
-
Astragalus Polysaccharide Enhances Voriconazole Metabolism under Inflammatory Conditions through the Gut Microbiota. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-04-19 Xiaokang Wang,Xianjing Hu,Chunxiao Ye,Jingqian Zhao,Shing Cheng Tan,Liangbin Zhou,Chenyu Zhao,Kit Hang Wu,Xixiao Yang,Jinbin Wei,Maoxun Yang
Background and Aims Voriconazole (VRC), a widely used antifungal drug, often causes hepatotoxicity, which presents a significant clinical challenge. Previous studies demonstrated that Astragalus polysaccharide (APS) can regulate VRC metabolism, thereby potentially mitigating its hepatotoxic effects. In this study, we aimed to explore the mechanism by which APS regulates VRC metabolism. Methods First
-
Bao-Gan-Xiao-Zhi-Wan Treatment Attenuates Methionine-choline-deficient Diet-induced Metabolic Dysfunction-associated Steatohepatitis in Rats by Modulating the NF-κB Signal Pathway and Autophagy. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-04-16 Liming Zhou,Xiaobin Zeng,Xiaofang Wei,Wanying Shen,Jie Yao,Weigang Wu,Lanlan Ge,Boping Zhou
-
Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-04-15 Jinlin Hou,Qin Ning,Zhongping Duan,Yu Chen,Qing Xie,Lunli Zhang,Shanming Wu,Hong Tang,Jun Li,Feng Lin,Yongfeng Yang,Guozhong Gong,Yanwen Luo,Shelley Xie,Hongyuan Wang,Roberto Mateo,Tahmineh Yazdi,Frida Abramov,Leland J Yee,John Flaherty,Chengwei Chen,Yan Huang,Mingxiang Zhang,Jidong Jia
Background and Aims After 3-years (144 week) of double-blind treatment in Chinese chronic hepatitis B patients in two ongoing phase 3 studies, tenofovir alafenamide (TAF) showed similar efficacy to tenofovir disoproxil fumarate (TDF), with improved renal and bone safety. In this study, we aimed to report the 5-year results from 2 years into the open-label TAF treatment phase. Methods All participants
-
Transjugular Intrahepatic Portosystemic Shunt Linked to Increased Risk of Hepatocellular Carcinoma: A VA Matched Cohort Study. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-04-08 Shalini Bansal,Tamar Taddei,Rebecca Wells,Marina Serper,Theresa Bittermann,Nadim Mahmud,David E Kaplan
-
Beneficial Effects of Traditional Chinese Medicine Fuzheng Huayu on the Occurrence of Hepatocellular Carcinoma in Patients with Compensated Chronic Hepatitis B Cirrhosis Receiving Entecavir: A Multicenter Retrospective Cohort Study. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-03-27 Haina Fan,Shujuan Lei,Zhimin Zhao,Yan Huang,Hui Wang,Xudong Liu,Xiaodong Li,Min Xu,Wei Zhang,Kewei Sun,Huichun Xing,Yang Mei,Jiaquan Huang,Chuanwu Zhu,Kejun Zhang,Yali Zong,Xizhong Shen,Qing Xie,Chenghai Liu
Background and Aims The application of antifibrotic drugs to treat patients with chronic liver diseases who are receiving antiviral therapies for hepatocellular carcinoma (HCC) has not been established. Here, we aimed to assess the impact of the Traditional Chinese Medicine Fuzheng Huayu (FZHY) on the occurrence of HCC in patients with hepatitis B virus-related compensated cirrhosis receiving the antiviral
-
Role of Fibrinogen-like Protein 1 in Tumor Recurrence Following Hepatectomy. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-03-25 Zahra Shafieizadeh,Zohreh Shafieizadeh,Maryam Davoudi,Reza Afrisham,Xiaolei Miao
Partial hepatectomy is a first-line treatment for hepatocellular carcinoma. Within 2 weeks following partial hepatectomy, specific molecular pathways are activated to promote liver regeneration. Nevertheless, residual microtumors may also exploit these pathways to reappear and metastasize. Therapeutically targeting molecules that are differentially regulated between normal cells and malignancies, such
-
Mortality Burden of Liver Cancer in China: An Observational Study From 2008 to 2020. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-03-19 Huixin Liu,Xiaoxiao Wang,Lijun Wang,Peng Yin,Feng Liu,Lai Wei,Yu Wang,Maigeng Zhou,Jinlei Qi,Huiying Rao
Background and Aims China accounts for nearly half of liver cancer deaths globally. A better understanding of the current liver cancer mortality will be helpful to establishing priorities for intervention and to decreasing the disease burden of liver cancer. The study aimed to explore and predict the mortality burden of liver cancer in China. Methods Data were extracted from the Disease Surveillance
-
A Revised Classification of Primary Iron Overload Syndromes. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-03-19 Yasuaki Tatsumi,Motoyoshi Yano,Shinya Wakusawa,Hiroaki Miyajima,Tetsuya Ishikawa,Shinsaku Imashuku,Atsuko Takano,Wataru Nihei,Ayako Kato,Koichi Kato,Hisao Hayashi,Kentaro Yoshioka,Kazuhiko Hayashi
Background and Aims The clinical introduction of hepcidin25 (Hep25) has led to a more detailed understanding of its relationship with ferroportin (FP) and divalent metal transporter1 in primary iron overload syndromes (PIOSs). In 2012, we proposed a classification of PIOSs based on the Hep25/FP system, which consists of prehepatic aceruloplasminemia, hepatic hemochromatosis (HC), and posthepatic FP
-
The Therapeutic Effects of Baicalein on the Hepatopulmonary Syndrome in the Rat Model of Chronic Common Bile Duct Ligation. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-03-18 Ziyang Zeng,Yuhao Lei,Chunyong Yang,Xianfeng Wu,Liang Zhang,Zhiyong Yang,Lin Chen,Xiaobo Wang,Karine Belguise,Yujie Li,Bin Yi
Background and Aims Hepatopulmonary syndrome (HPS) is characterized by arterial oxygenation defects due to pulmonary vascular dilation in liver disease. To date, liver transplantation remains the only effective treatment for HPS. This study aimed to explore the preventative role of baicalein in HPS development. Methods Sixty male rats were randomly assigned to three groups: sham, common bile duct ligation
-
Nonalcoholic Fatty Liver Disease: Changes in Gut Microbiota and Blood Lipids. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-03-18 Keen Yang,Jieying Zeng,Huaiyu Wu,Huiyu Liu,Zhimin Ding,Weiyu Liang,Linghu Wu,Ziwei Lin,Wenhui Huang,Jinfeng Xu,Fajin Dong
Background and Aims The global prevalence of nonalcoholic fatty liver disease (NAFLD) is 25%. This study aimed to explore differences in the gut microbial community and blood lipids between normal livers and those affected by NAFLD using 16S ribosomal deoxyribonucleic acid sequencing. Methods Gut microbiome profiles of 40 NAFLD and 20 non-NAFLD controls were analyzed. Information about four blood lipids
-
Subnormal Serum Liver Enzyme Levels: A Review of Pathophysiology and Clinical Significance. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-03-18 Elham M Youssef,George Y Wu
Subnormal levels of liver enzymes, below the lower limit of normal on local laboratory reports, can be useful diagnostically. For instance, subnormal levels of aminotransferases can be observed in vitamin B6 deficiency and chronic kidney disease. Subnormal alkaline phosphatase levels may indicate the presence of hypophosphatasia, Wilson's disease, deficiencies of divalent ions, or malnutrition. Subnormal
-
Liver Transplantation Reverses Hepatic Myelopathy in the Decompensated Phase of Cirrhosis: Case Report and Literature Review. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-03-13 Jiajun Li,Sile Wan,Fukai Wen,Qingyu Li,Yifeng Cui,Zhaoyang Lu,Han Lin
Hepatic myelopathy (HM) is a rare neurological complication in the end stage of many liver diseases and is characterized by bilateral spastic paraparesis without sensory and sphincter dysfunction. It occurs owing to metabolic disorders and central nervous system dysfunction associated with cirrhosis. Without timely and effective clinical intervention, the prognosis of these patients is devastating
-
Paclitaxel-induced Immune Dysfunction and Activation of Transcription Factor AP-1 Facilitate Hepatitis B Virus Replication. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-03-06 Shi Chen,Benhua Li,Wei Luo,Adeel Ur Rehman,Miao He,Qian Yang,Shunyao Wang,Jinjun Guo,Ling Chen,Xiaosong Li
Background and Aims Hepatitis B virus (HBV) reactivation is commonly observed in individuals with chronic HBV infection undergoing antineoplastic drug therapy. Paclitaxel (PTX) treatment has been identified as a potential trigger for HBV reactivation. This study aimed to uncover the mechanisms of PTX-induced HBV reactivation in vitro and in vivo, which may inform new strategies for HBV antiviral treatment
-
RAMP1 Protects Hepatocytes against Ischemia-reperfusion Injury by Inhibiting the ERK/YAP Pathway. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-02-29 Yongsheng Tang,Zenan Yuan,Xu Lu,Yingqiu Song,Shuguang Zhu,Chunhui Qiu,Qi Zhang,Binsheng Fu,Changchang Jia,Hua Li
Background and Aims Hepatic ischemia-reperfusion injury (HIRI) is a prevalent complication of liver transplantation, partial hepatectomy, and severe infection, necessitating the development of more effective clinical strategies. Receptor activity-modifying protein 1 (RAMP1), a member of the G protein-coupled receptor adapter family, has been implicated in numerous physiological and pathological processes
-
Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-02-28 Hongbin Wei,Chunlu Dong,Xun Li
Hepatocellular carcinoma (HCC) is a common cancer, and the body's immune responses greatly affect its progression and the prognosis of patients. Immunological suppression and the maintenance of self-tolerance in the tumor microenvironment are essential responses, and these form part of the theoretical foundations of immunotherapy. In this review, we first discuss the tumor microenvironment of HCC,
-
The Relationship between Viral Replication and the Severity of Hepatic Necroinflammatory Damage Changed before HBeAg Loss in Patients with Chronic Hepatitis B Virus Infection. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-02-27 Leijie Wang,Jian Wang,Kunyu Zhao,Lina Jiang,Xinxin Zhang,Jingming Zhao,Jie Li,Fengmin Lu
Background and Aims Disease progression of chronic hepatitis B virus (HBV) infection is driven by the interactions between viral replication and the host immune response against the infection. This study aimed to clarify the relationship between HBV replication and hepatic inflammation during disease progression. Methods Two cross-sectional, one validation cohort, and meta-analyses were used to explore
-
Late-onset Cholestasis with Paucity of Portal Area Secondary to HNF1β Deficiency in Adulthood: A Case Report. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-02-19 Xuemei Zhang,Kun Liu,Xiaona Lu,Wenlan Zheng,Jia Shi,Shihan Yu,Hai Feng,Zhuo Yu
Hepatocyte nuclear factor 1β (HNF1β) is essential for biliary development, while its genetic defect triggers the dysplasia of interlobular bile ducts, leading to life-threatening hepatitis and cholestasis. To date, this disorder has mainly been documented in neonates. Here, we report a case of cholestasis in an adult patient caused by a de novo HNF1β mutation. A liver biopsy revealed remarkable shrinkage
-
Prognostic Biomarkers for Hepatocellular Carcinoma Based on Serine and Glycine Metabolism-related Genes. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-02-09 Xufan Cai,Fang Xu,Zhaohong Wang,Hui Chen,Shengzhang Lin
Background and Aims Targeted therapy and immunotherapy have emerged as treatment options for hepatocellular carcinoma (HCC) in recent years. The significance of serine and glycine metabolism in various cancers is widely acknowledged. This study aims to investigate their correlation with the prognosis and tumor immune microenvironment (TIME) of HCC. Methods Based on the public database, different subtypes
-
Genetics of Gallstone Disease and Their Clinical Significance: A Narrative Review. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-02-08 Christopher J Costa,Minh Thu T Nguyen,Haleh Vaziri,George Y Wu
Gallstone (GS) disease is common and arises from a combination of genetic and environmental factors. Although genetic abnormalities specifically leading to cholesterol GSs are rare, there are clinically significant gene variants associated with cholesterol GSs. In contrast, most bilirubin GSs can be attributed to genetic defects. The pathogenesis of cholesterol and bilirubin GSs differs greatly. Cholesterol
-
BTF3L4 Overexpression Mediates APAP-induced Liver Injury in Mouse and Cellular Models. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-02-08 Junchao Lin,Aqiang Fan,Zhujin Yifu,Qibing Xie,Liu Hong,Wei Zhou
Background and Aims Acetaminophen (APAP)-induced liver injury (AILI) has an increasing incidence worldwide. However, the mechanisms contributing to such liver injury are largely unknown and no targeted therapy is currently available. The study aimed to investigate the effect of BTF3L4 overexpression on apoptosis and inflammation regulation in vitro and in vivo. Methods We performed a proteomic analysis
-
Serum Iron Overload Activates the SMAD Pathway and Hepcidin Expression of Hepatocytes via SMURF1. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-02-04 Ning Zhang,Pengyao Yang,Yanmeng Li,Qin Ouyang,Fei Hou,Guixin Zhu,Bei Zhang,Jian Huang,Jidong Jia,Anjian Xu
Background and Aims Liver iron overload can induce hepatic expression of bone morphogenic protein (BMP) 6 and activate the BMP/SMAD pathway. However, serum iron overload can also activate SMAD but does not induce BMP6 expression. Therefore, the mechanisms through which serum iron overload activates the BMP/SMAD pathway remain unclear. This study aimed to clarify the role of SMURF1 in serum iron overload
-
Impact of Onset Time, Number, Type, and Sequence of Extrahepatic Organ Failure on Prognosis of Acute-on-chronic Liver Failure. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-01-31 Shaotian Qiu,Qian Zhang,Jiaxuan Hu,Lewei Wang,Rui Chen,Yingying Cao,Fang Liu,Zhenjun Yu,Caiyan Zhao,Liaoyun Zhang,Wanhua Ren,Shaojie Xin,Yu Chen,Zhongping Duan,Tao Han
Background and Aims The impact of the characteristics of extrahepatic organ failure (EHOF) including the onset time, number, type, and sequence on the prognosis of acute-on-chronic liver failure (ACLF) patients remains unknown. This study aimed to identify the association between the characteristics of EHOF and the prognosis of ACLF patients. Methods ACLF subjects enrolled at six hospitals in China
-
Progress in Biomarkers Related to Biliary Atresia. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-01-30 Fanyang Kong,Rui Dong,Gong Chen,Song Sun,Yifan Yang,Jingying Jiang,Lingdu Meng,Huifen Chen,Jiajie Zhu,Shan Zheng
Biliary atresia (BA) is a congenital cholestatic disease that can seriously damage children's liver function. It is one of the main reasons for liver transplantation in children. Early diagnosis of BA is crucial to the prognosis of patients, but there is still a lack of reliable non-invasive diagnostic methods. Additionally, as some children are in urgent need of liver transplantation, evaluating the
-
A Novel Algorithm for Streamlining Diagnosis of Advanced Liver Fibrosis in CHB Patients with Concurrent Hepatic Steatosis. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-01-29 Xiaoming Xu,Fajuan Rui,Wenjing Ni,Chao Wu,Junping Shi,Jie Li
-
Approaching the Sarcopenic Patient with Nonalcoholic Steatohepatitis-related Cirrhosis. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-01-26 Paolo Gallo,Valentina Flagiello,Andrea Falcomatà,Giulia Di Pasquale,Giorgio D'Avanzo,Francesca Terracciani,Antonio Picardi,Umberto Vespasiani-Gentilucci
Sarcopenia is a well-known complication of chronic liver disease (CLD), and it is almost always observed in patients with cirrhosis, at least in those with decompensated disease. Since nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is becoming the leading cause of end-stage liver disease, a new scenario characterized by the
-
Effects of the Pituitary-targeted Gland Axes on Hepatic Lipid Homeostasis in Endocrine-associated Fatty Liver Disease-A Concept Worth Revisiting. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-01-23 Yifang Li,Meina Zheng,Steven Limbara,Shanshan Zhang,Yutao Yu,Le Yu,Jian Jiao
Hepatic lipid homeostasis is not only essential for maintaining normal cellular and systemic metabolic function but is also closely related to the steatosis of the liver. The controversy over the nomenclature of non-alcoholic fatty liver disease (NAFLD) in the past three years has once again sparked in-depth discussions on the pathogenesis of this disease and its impact on systemic metabolism. Pituitary-targeted
-
Trends in Mortality of Cirrhosis in China: An Analysis of the China Death Surveillance Database from 2008 to 2020. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-01-22 Xiaoxiao Wang,Huixin Liu,Jinlei Qi,Lijun Wang,Peng Yin,Feng Liu,Lai Wei,Yu Wang,Maigeng Zhou,Huiying Rao
Background and Aims China accounts for 14.9% of total cirrhosis deaths worldwide. A detailed and comprehensive understanding of the contemporary status of cirrhosis mortality in China is crucial for establishing strategies for intervention and decreasing the disease burden of cirrhosis worldwide. The study aimed to report the cirrhosis mortality rates in our whole country or province over time. Methods
-
Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-01-10 Qi-Feng Chen,Song Chen,Minshan Chen,Ning Lyu,Ming Zhao
The high mortality rate in hepatocellular carcinoma (HCC) is partially due to the fact that a significant number of patients are diagnosed at an intermediate or advanced stage, with surgical treatment options unavailable. Conversion therapy, which involves both locoregional and systemic treatments, has the potential to downstage tumors in selected patients with initially unresectable HCC, thereby making
-
Immune Regulatory Networks and Therapy of γδ T Cells in Liver Cancer: Recent Trends and Advancements. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-01-08 Kun-Li Yin,Kai-Jian Chu,Ming Li,Yu-Xin Duan,Yan-Xi Yu,Mei-Qing Kang,Da Fu,Rui Liao
The roles of γδ T cells in liver cancer, especially in the potential function of immunotherapy due to their direct cytotoxic effects on tumor cells and secretion of important cytokines and chemokines, have aroused research interest. This review briefly describes the basic characteristics of γδ T cells, focusing on their diverse effects on liver cancer. In particular, different subtypes of γδ T cells
-
Hepatocellular Carcinoma Incidence and Mortality in the USA by Sex, Age, and Race: A Nationwide Analysis of Two Decades. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-01-02 Yazan Abboud,Mohamed Ismail,Hamza Khan,Esli Medina-Morales,Saqr Alsakarneh,Fouad Jaber,Nikolaos T Pyrsopoulos
Background and Aims While the incidence rates of hepatocellular carcinoma (HCC) are increasing, there are limited comprehensive data on demographic-specific incidence and mortality trends in the USA. We aimed to evaluate recent trends in HCC incidence and mortality among different demographic groups in the USA. Methods Age-adjusted HCC incidence rates were calculated from the Centers for Disease Control's
-
Focal Nodular Hyperplasia: A Comprehensive Review with a Particular Focus on Pathogenesis and Complications. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2024-01-02 Jaimy Villavicencio Kim,George Y Wu
Focal nodular hyperplasia is a benign tumor of the liver that is often found incidentally with imaging. The purpose of this review is to discuss the pathophysiology, rare complications that can occur due to these lesions, and management options. A literature review was performed on clinical trials and case reports involving focal nodular hyperplasia complications and management of these, as well as
-
-
Predictive Model of Oxaliplatin-induced Liver Injury Based on Artificial Neural Network and Logistic Regression. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2023-12-04 Rui Huang,Yuanxuan Cai,Yisheng He,Zaoqin Yu,Li Zhao,Tao Wang,Xiaofang Shangguan,Yuhang Zhao,Zherui Chen,Yunzhou Chen,Chengliang Zhang
Background and Aims Identifying potential high-risk groups of oxaliplatin-induced liver injury (OILI) is valuable, but tools are lacking. So artificial neural network (ANN) and logistic regression (LR) models will be developed to predict the risk of OILI. Methods The medical information of patients treated with oxaliplatin between May and November 2016 at 10 hospitals was collected prospectively. We
-
Causal Relationship Between Gut Microbiota and Liver Cirrhosis: 16S rRNA Sequencing and Mendelian Randomization Analyses. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2023-11-30 Mengqin Yuan,Xue Hu,Lichao Yao,Ping Chen,Zheng Wang,Pingji Liu,Zhiyu Xiong,Yingan Jiang,Lanjuan Li
Background and Aims Accumulating evidence highlights the association between the gut microbiota and liver cirrhosis. However, the role of the gut microbiota in liver cirrhosis remains unclear. Methods We first assessed the differences in the composition of the bacterial community between CCl4-induced liver cirrhosis and control mice using 16S rRNA sequencing. We then performed a two-sample Mendelian
-
Liver Lesions at Risk of Transformation into Hepatocellular Carcinoma in Cirrhotic Patients: Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement. J. Clin. Transl. Hepatol. (IF 3.1) Pub Date : 2023-11-29 Nicolò Brandi,Matteo Renzulli
Recent technical advances in liver imaging and surveillance for patients at high risk for developing hepatocellular carcinoma (HCC) have led to an increase in the detection of borderline hepatic nodules in the gray area of multistep carcinogenesis, particularly in those that are hypointense at the hepatobiliary phase (HBP) and do not show arterial phase hyperenhancement. Given their potential to transform